---
title: "Cuvo vs OpenLoop"
description: "White-label telehealth that owns your billing and keeps 50 to 59 percent of every maintenance patient's payment."
canonical: "https://cuvo.co/compare/cuvo-vs-openloop"
last-updated: "Aug 23, 2026"
---
# Cuvo vs OpenLoop: the 2026 comparison (Revenue-share telehealth platform)

Facts last reviewed Aug 23, 2026. OpenLoop: https://openloophealth.com

OpenLoop rents you a telehealth clinic, then keeps 50 to 59 percent of every maintenance patient's payment, forever, while owning your merchant account, card tokens, and patient data. Cuvo charges flat fees, marks up nothing, and leaves you owning all of it. Here is the line-by-line math.

Prepared July 2026 · Based on OpenLoop's own written proposal (05/28/26 expiration), Cuvo's 05/01/2026 medication price list, Cuvo commercial terms, and publicly verifiable third-party sources. Shipping costs excluded from all calculations per scope.

## 01. Executive summary: Cuvo vs OpenLoop

OpenLoop and Cuvo both offer white-label telehealth infrastructure: clinicians, EHR, e-prescribing, pharmacy fulfillment, and compliance. The similarity ends there. The two operate on fundamentally opposite business models:

**OpenLoop is a revenue-share landlord.** Patients pay into *OpenLoop's* merchant account. OpenLoop owns the billing relationship, the credit card tokens, and the patient data pipeline, then remits a "Membership Services Fee" back to you weekly. On maintenance patients, OpenLoop retains **50–59% of every dollar your patient pays**, indefinitely, on every patient, forever.

**Cuvo is a flat-fee utility.** Patients pay *you* first, into *your* merchant account. Cuvo passes medications through at $0 markup, charges a flat $25 per consultation, and takes no per-patient cut whatsoever. Your margin scales with you; Cuvo's revenue doesn't grow when yours does.

On identical retail pricing, a clinic nets roughly **35–90% more per maintenance patient per month on Cuvo**, and that's before considering that on OpenLoop you never own your merchant account, card tokens, or billing relationship, which is precisely what makes leaving OpenLoop so difficult. Add a January 2026 data breach affecting ~716,000 downstream patients, sub-3-star employer ratings, and a review-generation practice that puts OpenLoop's brand in front of *your* patients, and the picture is clear.

## 02. Business model and money flow

|  | Cuvo | OpenLoop |
| --- | --- | --- |
| Who charges the patient | **You**: your interface, your merchant account | OpenLoop: patient card charged into **OpenLoop's merchant account** |
| Who owns the merchant account | **You** | OpenLoop ("merchant account management... is OpenLoop's responsibility") |
| Who owns the credit card tokens | **You** | OpenLoop |
| Who owns patient records | **You** | OpenLoop's EHR holds patient processing; data lives in their system |
| When you get paid | **Immediately: money hits your account first** | Weekly remittance: "every Wednesday for the week ending Tuesday," calculated by OpenLoop from *their* count of net active patients |
| Revenue model | Flat fees only: $0 med markup, $25/consult, no per-patient fee | Retains the spread between what the patient pays and what they remit to you (typically 42–59% of patient revenue) |
| Your pricing freedom | Set any retail price; your margin is yours | Retail prices and your remittance are fixed in their schedule; changing your economics means renegotiating with OpenLoop |
| Payment methods | Your merchant account: your choice (incl. Amex if you want) | Visa, MC, FSA/HSA, Apple Pay, Google Pay, but **no American Express** |

**Why this matters more than any single fee:** on OpenLoop, your entire revenue stream (every card token, every subscription billing record, every patient chart) lives inside OpenLoop's stack. Migrating away means re-acquiring payment authorization from every single patient and rebuilding billing from zero. That is functionally a customer-base reset, and it's the quiet mechanism that keeps clinics locked in regardless of how the relationship goes. On Cuvo, you could switch pharmacies, switch doctors, or leave entirely tomorrow and your business would be intact, because **you already own everything that matters**: records, tokens, merchant account, and cash flow.

## 03. Fixed costs and contract terms

|  | Cuvo | OpenLoop |
| --- | --- | --- |
| Setup / implementation fee | **$9,800** (Launch program) | **$9,000** ($4,500 at signing, $4,500 at first patient) |
| LegitScript certification | **Expedited certification included FREE** ($5,625 standalone value) | **+$3,000** flat fee (optional add-on, expedited) |
| Effective upfront cost with LegitScript | **$9,800** | **$12,000** |
| Monthly platform fee | **$997 flat** on Launch, month to month | **$1,500/mo from first patient seen** |
| Contract commitment | **Month-to-month. No term.** | **12-month initial term** |
| Adding new business lines | Included: same flat model; anything beyond core is a purely optional add-on | Requires MSA addendum **plus a separate implementation fee** |
| Year-1 fixed outlay | **$21,764** ($9,800 + $997 x 12) | **$30,000** ($9,000 + $3,000 LegitScript + $1,500 x 12) |
| Year-2+ fixed outlay | **$11,964/yr** | **$18,000/yr** |

> **Comparison basis** Cuvo figures use the **Launch program**, the entry tier at $997 a month with a $9,800 setup, because it is the tier that matches OpenLoop's single quoted rate. Cuvo also publishes **Grow at $2,000 a month ($15,000 setup)** and a **custom-priced Enterprise program** for operators who want automation, integrations and multi-brand operations; every tier carries identical commercial terms (month to month, $25 consults, 0% medication markup, no cut of your revenue). Whichever tier you pick, the fixed-fee gap is the smaller half of this comparison: the per-patient economics below dwarf it at any real patient count.

Year one on OpenLoop runs **$30,000 in fixed fees, contractually locked for 12 months**, versus **$21,764 on Cuvo with zero commitment**: an $8,236 (27%) saving before a single patient-level dollar is counted. The gap persists at steady state ($11,964/yr vs. $18,000/yr), Cuvo's upfront is $2,200 lower with expedited LegitScript already inside it, and Cuvo's $997 covers everything needed to run the clinic; anything beyond that is a genuinely optional add-on, not a required addendum with its own implementation fee. If your launch stalls, your funnel underperforms, or you simply want to change direction, OpenLoop holds you to the term; Cuvo lets you walk any month.

## 04. Per-patient economics: where the real money is

OpenLoop's proposal is transparent about its mechanism: the middle column is what your patient pays, the right column is what you receive, and "the difference... is what is retained by OpenLoop." Below, we hold retail price constant (using OpenLoop's own price points) and compute what the same patient is worth on each platform. Cuvo figures = retail - medication cost (Cuvo's at-cost price list, lowest to highest dose level) - $25 consult in month 1 and quarterly thereafter (~$8/mo amortized at steady state). Shipping excluded from both sides.

**Semaglutide injection: $249/mo retail**

| Month | Patient pays | You net on OpenLoop | You net on Cuvo | Cuvo advantage |
| --- | --- | --- | --- | --- |
| Month 1 (with consult) | $249 | $140 | **$156–$189** | +$16 to +$49 |
| Month 5+ (maintenance) | $249 | $124 | **$173–$206** | **+$49 to +$82 (+39–66%)** |
| **12-month patient value** | $2,988 | **$1,514** | **$2,047–$2,443** | **+$533 to +$929 per patient** |

**Tirzepatide injection: $339/mo retail**

| Month | Patient pays | You net on OpenLoop | You net on Cuvo | Cuvo advantage |
| --- | --- | --- | --- | --- |
| Month 1 | $339 | $196 | $169–$246 | -$27 to +$50 |
| Month 5+ (maintenance) | $339 | **$138** | **$186–$263** | **+$48 to +$125 (+35–90%)** |

Note what happens on OpenLoop's tirzepatide maintenance line: the patient pays $339 and you receive $138, and **OpenLoop keeps $201, or 59% of your patient's payment, every month, forever.** On Cuvo, even at the highest dose tier (Level 6, $145/vial), that same dollar goes 35% further to you; at typical mid-titration doses the gap approaches double.

**Semaglutide oral ODT: $279/mo retail**

| Month | Patient pays | You net on OpenLoop | You net on Cuvo | Cuvo advantage |
| --- | --- | --- | --- | --- |
| Month 1 | $279 | $136 | $155–$188 | +$19 to +$52 |
| Month 5+ | $279 | $128 | **$172–$205** | **+$34 to +$77 (+34–60%)** |

## The prepay penalty on long commitments

OpenLoop's long-commitment tiers compound the problem. On the 52-week semaglutide injection plan, the patient pays $2,327 and you receive $1,076, and OpenLoop retains **$1,251 (54%)** of a patient who committed to you for a year. On Cuvo, a 52-week patient at even a discounted $179/mo retail nets you roughly $1,400–$1,700 after meds and consults, on a patient paying *less*.

**Scale math**

| Maintenance patients | Extra annual profit on Cuvo (sema inj, conservative +$49/mo) | (typical +$80/mo) |
| --- | --- | --- |
| 100 | +$58,800/yr | +$96,000/yr |
| 500 | +$294,000/yr | +$480,000/yr |
| 1,000 | +$588,000/yr | +$960,000/yr |

The fixed-fee difference between the platforms is rounding error next to this. **OpenLoop's model taxes your growth; Cuvo's doesn't.**

> **Fairness note** OpenLoop's spread does bundle billing, clinical consults, base MWL labs, patient support, and medication cost into their retained share. But on Cuvo, consults are $25 flat and meds are at cost, so those same services cost you dramatically less than the 50–59% OpenLoop prices them at, and you keep the difference.

## 05. Flexibility and vendor independence

|  | Cuvo | OpenLoop |
| --- | --- | --- |
| Pharmacy network | **17 pharmacies**, or **bring your own** (Cuvo doesn't profit on meds, so has no incentive to block it) | OpenLoop's supply chain only; fulfillment and med costs run through them |
| Provider network | In-house doctor network, or **bring your own doctors** | OpenLoop-recruited/credentialed providers on their platform |
| Care model control | Yours | Defined in OpenLoop's schedules (consult cadence, age limits, program structure); "availability of any given GLP-1 option may change at any time, with no notice" |
| Exit path | Walk away any month with your records, tokens, merchant account, and patients | 12-month term; patient billing, tokens, and records live in OpenLoop's systems |

This is the structural point: because Cuvo makes no margin on medications or providers, it has **no conflict of interest** in letting you route around it. OpenLoop's economics depend on being the toll booth between you and your patients.

## 06. Reputation, trust, and risk

## The January 2026 data breach: 716,000 patients exposed

This is not a rumor; it is confirmed on the HHS Office for Civil Rights breach portal and reported to the California and Texas Attorneys General. On January 7, 2026, an unauthorized third party accessed OpenLoop's systems and exfiltrated files containing patient names, addresses, email addresses, dates of birth, and medical information, affecting up to 716,000 individuals across the telehealth brands running on OpenLoop's infrastructure. A threat actor ("Stuckin2019") publicly claimed 1.6 million records and posted samples as proof. The affected population "spans patients across multiple client organizations rather than direct OpenLoop consumers," meaning **it was OpenLoop's clients' patients, under their clients' brand names, whose data was stolen.**

For a clinic evaluating OpenLoop, the lesson is architectural, not just reputational: OpenLoop's model *requires* concentrating 120+ brands' worth of patient data in one honeypot. When it was breached, every downstream clinic inherited the incident (the notification obligations, the patient trust damage, the churn) for a security failure they had zero control over. On Cuvo's model, you own and control your patient records.

## The Google reviews illusion

OpenLoop shows 1,197 Google reviews averaging 4.5 stars, impressive until you read them. The reviews are overwhelmingly from *patients of client clinics* ("clinician was very attentive," "how fast my order was delivered by FedEx," "waiting on my prescription"), not from clinic operators evaluating OpenLoop as a B2B vendor. Per operator reports, OpenLoop generates these by emailing *the client clinics' patients* and soliciting reviews for OpenLoop, a practice with two problems:

1. **It breaks the white label.** The entire premise of the product is that your patients never know a third party is behind your brand. Soliciting your patients to publicly review OpenLoop puts OpenLoop's name directly in front of them.
2. **It makes the rating unusable as a B2B signal.** A patient's 5-star FedEx delivery experience tells you nothing about how OpenLoop treats the clinics that are its actual customers.

## What people who actually deal with OpenLoop say

The B2B-relevant signals point the other way:

| Source | Rating | Detail |
| --- | --- | --- |
| **Glassdoor** | **2.8 / 5** | Only **33% would recommend to a friend**; **37% approve of the CEO**; 45% positive business outlook (100 reviews) |
| **Indeed** | **2.4 / 5** | 51 reviews; heavily 1-star-weighted distribution; Job security & advancement rated **1.9**; reviewers flag lack of "trust in colleagues" (updated May 31, 2026) |

Employee reviews aren't client reviews, but they are a leading indicator of service quality: a company whose own staff rate job security at 1.9/5 and where barely a third would recommend working there is a company with turnover and morale problems, and turnover in credentialing, support, and account management lands directly on clients. Combined with operator reports of being "treated like a number on a take-it-or-leave-it basis" once signed, the 4.5-star Google facade and the 2.4–2.8 insider reality tell two very different stories.

## 07. The fine print: fifteen red flags inside OpenLoop's own proposal

Cuvo's team obtained an actual OpenLoop proposal (a "Summary of Proposed Services" prepared for a prospective clinic, complete with pricing schedules, program terms, and contract structure) and went through it line by line. Everything below is drawn directly from that document; nothing is paraphrased from marketing or hearsay. Read individually, each item is a concession; read together, they describe a contract engineered so that risk flows to the client and margin flows to OpenLoop.

1. **The maturity penalty: OpenLoop's cut grows the longer you keep a patient.** On tirzepatide, the patient pays the same $339 every month, but your remittance falls from $196 in month 1 to $138 at month 5+, while OpenLoop's take climbs from $143 (42%) to $201 (59%). That's a **41% increase in OpenLoop's cut and a 30% drop in your revenue on the identical patient paying the identical price.** Retention is the hardest thing to earn in telehealth; this schedule is built so that the fruits of *your* retention accrue to OpenLoop.
2. **You fund the patient discounts on long-term plans.** On the 52-week semaglutide plan, the patient's price drops 28% (from $249 to $179/cycle), but your remittance drops **33%** (from $124 to ~$83/cycle). OpenLoop offers your patients a discount and makes you absorb a disproportionate share of it.
3. **OpenLoop holds the float on annual prepayments.** A 52-week tirzepatide patient pays **$3,497 on day one, into OpenLoop's merchant account.** Your $1,572 share arrives dripped out weekly, contingent on OpenLoop's own determination that the patient is "active." OpenLoop banks a year of your patients' cash up front; you get yours on layaway.
4. **OpenLoop counts, OpenLoop calculates, you get what they say.** Your weekly payment is "based on count of net active patients for the week by Month Cohort," with active status "determined by successful credit card charge," all measured inside systems only OpenLoop can see. The proposal grants no audit rights, no reporting standard, and no recourse if their count and yours disagree. "Net" active also implies refunds and chargebacks are clawed back from *your* remittance.
5. **OpenLoop sets the refund policy for your customers.** The proposal dictates that patients "may request refund for any reason at any time." A generous refund policy is defensible, but it's imposed unilaterally, on revenue that flows through OpenLoop's account, with the resulting losses netted against your share. You carry refund exposure on a policy you didn't write and can't change.
6. **Reserves and hold-backs on your revenue.** OpenLoop explicitly manages "reserves/hold-backs" on the merchant account. Standard merchant practice, except it's *your patients' payments* being reserved, at a percentage and duration you don't control, by a counterparty you can't audit. Structurally, you are an unsecured creditor of OpenLoop for every dollar in transit.
7. **Your product can vanish overnight, and that's in writing.** "Availability of any given GLP-1 option may change at any time, *with no notice*." If a patient's medication disappears, OpenLoop will "attempt" to find an alternative, but "not all patients will qualify." Your core offering (the thing your marketing spend acquired patients for) exists at OpenLoop's pleasure, and they've pre-disclaimed any obligation when it doesn't.
8. **Pricing is a moving target with a signature deadline.** The proposal expires in 30 days and states pricing "will change immediately upon changes in FDA and state regulations." Combined with flag #7, you're asked to sign a 12-month commitment against pricing and product availability that OpenLoop reserves the right to change at any moment.
9. **You're asked to sign against blanks.** An upfront implementation fee is normal, and what's not normal is what's *behind* it. In OpenLoop's proposal, the provider quantities in Schedule A are literally "TBD," the staff start date is "tbd," and holiday coverage is explicitly excluded, yet $4,500 is due at signature and the 12-month clock starts anyway. You're committing to a year against a staffing plan that hasn't been written. And the scope you're buying is deliberately narrow: every future business line triggers "an addendum to the MSA and a separate implementation fee": expansion is a tollbooth, not a feature. (Contrast: Cuvo's $9,800 Launch setup buys a fully defined offering: the complete 05/01/2026 price list, the 17-pharmacy network, the consult rate, and the LegitScript certification, with no term, no per-line addendums, and no re-implementation fees to grow.)
10. **The margins on commodity products are indefensible.** On the sexual-health single-dose 10-pack, the patient pays $119 and you receive $50, and OpenLoop keeps **58%** on generic sildenafil/tadalafil that costs roughly a dollar a dose at compounding cost. The best example: the **biotin supplement**: patient pays $35/month, you receive $11, and OpenLoop keeps **$24 (69%) on an over-the-counter vitamin.** These aren't clinical-services margins; they're what a captive channel looks like.
11. **Coverage and eligibility carve-outs hide behind the "50-state" headline.** TRT with scheduled medications is available in only ~35 listed states ("subject to change at any time"). Weight loss is capped at ages 18–74, TRT at 25+, sexual health at 21+ with 75+ restricted to single-ingredient products. Staffing "does not include holiday coverage." OpenLoop defines your addressable market, and reserves the right to redefine it without notice.
12. **The proposal can't even keep its own numbers straight.** The microdosing table lists the 24-week option as "$159/mo (charged as $507)" and the 52-week option as "$149/mo (charged as $507)": the same $507 for both, when the stated monthly rates imply roughly $954 and $1,937 respectively. A pricing document with internally contradictory numbers is either careless or convenient; either way, it's what the contract will incorporate by reference, and *you'd* be the one discovering which figure OpenLoop honors after signing. (Note also: TRT care coaching is "$5 per patient per month **(waived)**," waived, not removed. The right to start charging is retained.)
13. **"Paid by OpenLoop" means deducted from you.** The tables tout "(labs paid by OpenLoop)" in Month 2, and in exactly that month your remittance drops $12 on semaglutide and $30 on tirzepatide. The "optional" Care Coaching works identically: the care-coaching-included tables carry a footnote confirming a "$10 per 4-week reduction in Admin Fee," and every figure in *your* column falls by precisely $10 while OpenLoop's retained share is untouched. Across the entire proposal, not one cost is ever absorbed on OpenLoop's side of the ledger.
14. **The termination clause is a loaded gun pointed one way.** "12-month initial term, 30 day notice to terminate for any reason." Read it from both sides. If *you* terminate, you leave behind your merchant account, card tokens, billing relationships, and patient records (all resident in OpenLoop's stack) and effectively restart from zero. If *OpenLoop* terminates, they lose one revenue-share client and keep everything. A mutual 30-day clause between parties with wildly asymmetric switching costs isn't mutual at all: it's a kill switch on your business that only one side can afford to pull.
15. **Even your legitimacy credential may be a tether.** Before considering the $3,000 "LegitScript Through OpenLoop Integration," ask in writing: if certification is obtained *through OpenLoop's integration*, does it survive your departure from the platform? The proposal is silent. (Cuvo's included expedited LegitScript certification is yours outright, a $5,625 standalone value, free.)

**The pattern across all fifteen:** OpenLoop holds the cash, the count, the policy, the product availability, the pricing, and the exit. The client holds the brand risk, the marketing cost, the refund exposure, and a 12-month obligation. Cuvo's flat-fee model doesn't just price better, it structurally *can't* do most of the above, because Cuvo never touches your money, your tokens, or your patient relationships in the first place.

## 08. Side-by-side scorecard

| Criterion | Cuvo | OpenLoop | Winner |
| --- | --- | --- | --- |
| Upfront cost (with LegitScript) | $9,800 all-in (Launch) | $12,000 | **Cuvo ($2,200 less)** |
| Monthly fee | $997 flat on Launch, month to month | $1,500 from first patient | **Cuvo** |
| Contract | Month-to-month | 12-month term | **Cuvo** |
| Medication pricing | At cost, $0 markup | Bundled into 42–59% revenue retention | **Cuvo** |
| Consultation pricing | $25 flat | Bundled into retention | **Cuvo** |
| Per-patient fees | None | Effectively 50–59% of maintenance revenue | **Cuvo** |
| Merchant account ownership | Clinic | OpenLoop | **Cuvo** |
| Card token ownership | Clinic | OpenLoop | **Cuvo** |
| Patient record ownership | Clinic | OpenLoop's systems | **Cuvo** |
| Cash flow | Direct to clinic, immediately | Weekly remittance from OpenLoop | **Cuvo** |
| Pharmacy flexibility | 17 pharmacies or BYO | OpenLoop supply chain only | **Cuvo** |
| Provider flexibility | In-house network or BYO | OpenLoop providers only | **Cuvo** |
| Exit/migration | Trivial: you own everything | Effectively a business reset | **Cuvo** |
| Data breach history | None known | 716K patients, Jan 2026, HHS-confirmed | **Cuvo** |
| White-label integrity | Fully invisible to patients | Solicits reviews from clients' patients | **Cuvo** |
| Employer ratings (service-quality proxy) | n/a | Glassdoor 2.8, Indeed 2.4 | n/a |
| 50-state coverage | Yes (cold-chain injectables all 50; most others all states exc. DC, some exc. CA) | Yes (all 50 + DC) | Comparable |
| Amex acceptance | Your choice | Not accepted | **Cuvo** |

## 09. Bottom line: follow the money

OpenLoop's proposal reads well until you follow the money. You pay $2,200 more upfront, sign for twelve months against pricing OpenLoop can change at any moment and product availability it can pull "with no notice," surrender your merchant account, your card tokens, and your patient data pipeline, and then hand over half or more of every maintenance patient's payment (a cut that *grows* as your patients stay longer) to a vendor with an HHS-confirmed 716,000-patient breach, bottom-quartile employee sentiment, a 69% margin on a drugstore vitamin, and a review practice that markets itself to your patients.

Cuvo's Launch program charges $9,800 once, includes the $5,625 LegitScript expedited certification free, charges a flat $997 a month, binds you to nothing, marks up nothing, and leaves you owning every asset that makes a telehealth clinic a business: the patients, the records, the tokens, the merchant account, and the margin. Year one you spend $21,764 on Cuvo versus $30,000 locked in on OpenLoop, and at 500 maintenance patients, the per-patient model difference alone is worth roughly $300K–$480K a year on top of that.

One platform is built to make money *when you do*. The other is built to make money *from* you. That's the choice.

## 10. Common questions about OpenLoop and Cuvo

**Q: How much does OpenLoop cost?**

A: OpenLoop's proposal prices implementation at $9,000, split $4,500 at signing and $4,500 at first patient, with expedited LegitScript certification as a $3,000 add-on and a $1,500 monthly fee from the first patient seen, all on a 12-month initial term. The larger cost is the revenue model: on maintenance patients OpenLoop retains roughly 50 to 59 percent of what the patient pays. Cuvo's equivalent figures, on its Launch program, are $9,800 once with LegitScript included and $997 a month, month-to-month, with no per-patient cut. Cuvo also publishes a larger Grow program at $2,000 a month with a $15,000 setup, and a custom-priced Enterprise program, on the same terms.

**Q: Does OpenLoop take a revenue share?**

A: Structurally, yes. Patients pay into OpenLoop's merchant account, and OpenLoop remits a scheduled amount back to the clinic weekly, keeping the difference. On its own proposal's numbers, a maintenance tirzepatide patient pays $339 a month and the clinic receives $138, so OpenLoop retains $201, about 59 percent, every month the patient stays.

**Q: Who owns the patient data and billing on OpenLoop?**

A: OpenLoop does. Patient payments run through OpenLoop's merchant account, the card tokens live in OpenLoop's systems, and patient records sit in OpenLoop's EHR. Leaving the platform means re-acquiring payment authorization from every patient and rebuilding billing from zero. On Cuvo, the merchant account, tokens, and records are the clinic's from the first transaction.

**Q: Did OpenLoop have a data breach?**

A: Yes. On January 7, 2026, an unauthorized third party accessed OpenLoop's systems and exfiltrated files affecting up to 716,000 patients across the telehealth brands running on its infrastructure. The incident is confirmed on the HHS Office for Civil Rights breach portal and was reported to the California and Texas Attorneys General.

**Q: What is the best OpenLoop alternative?**

A: It depends on which model you want to be on. OpenLoop bundles clinicians, billing, and fulfillment into a revenue-retention model with a 12-month term. A clinic that wants flat published fees, medications at cost, a $25 consult rate, no term, and ownership of its merchant account, card tokens, and patient records is the buyer Cuvo was built for; the line-by-line math is above.

*Sources and disclosures: Sources: OpenLoop "Summary of Proposed Services" (exp. 05/28/26); Cuvo/RxAve client price list dated 05/01/2026; Cuvo commercial terms; HHS OCR breach portal via SecurityWeek, HIPAA Journal, Security Affairs (May 2026); Glassdoor and Indeed company pages (screenshots, May 2026). Cuvo fixed-fee figures quote the Launch program ($997 a month, $9,800 setup); Grow and Enterprise are published on Cuvo's pricing page and carry the same commercial terms. Per-patient figures exclude shipping on both platforms and assume identical retail pricing. OpenLoop is a trademark of its respective owner, which is not affiliated with Cuvo Health and does not endorse this comparison. Not legal or financial advice; verify contract terms against executed agreements.*

*Competitor information comes from the public sources above as of Aug 23, 2026; unknowns are stated as not publicly listed rather than asserted. Cuvo claims restate what cuvo.co publishes elsewhere.*

Canonical page: https://cuvo.co/compare/cuvo-vs-openloop